Reaction
Precancerous Skin Lesion reporting signals
As of the last recalculation, Precancerous Skin Lesion appears in 1,456 FAERS reports alongside 8 co-occurring drug terms. The strongest observed disproportionality signal is RISANKIZUMAB-RZAA (PRR 15.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Risankizumab-Rzaa | 86 | 15.9 | 15.9 |
| Adalimumab | 348 | 8.9 | 8.9 |
| Ibrutinib | 43 | 7.8 | 7.8 |
| Naproxen Sodium Tablet, Coated | 7 | 7.4 | 7.4 |
| Naproxen Sodium, Coated Tablets | 7 | 7.4 | 7.4 |
| Naproxen Sodium 220Mg | 7 | 7.4 | 7.4 |
| Ruxolitinib | 35 | 7.1 | 7.1 |
| Acalabrutinib | 5 | 5.9 | 5.9 |